Key result
The overall prevalence of laboratory defined aspirin resistance in cardiovascular disease patients was 24.7% (95% CI 21.4-28.4).
Why the study?
Aspirin is the gold standard for thrombotic disease prevention in CVD, but not all individuals respond similarly and can be resistant to aspirin.
What is the prevalence of laboratory defined aspirin resistance in patients with cardiovascular disease?
Meta-Analysis (n=10,729)
What is the prevalence of laboratory defined aspirin resistance in patients with cardiovascular disease?
Laboratory-defined aspirin resistance is highly prevalent (24.7%) among cardiovascular disease patients, suggesting a substantial proportion may not receive optimal antiplatelet protection.
High prevalence signals many patients may have suboptimal aspirin response; leaves open whether testing or regimen changes improve outcomes.
BACKGROUND: Cardiovascular disease (CVD) is the first cause of mortality worldwide, with all the healthcare systems facing this very challenging issue. Aspirin continues to be the major gold-standard treatment worldwide in the prevention of thrombotic disease in patients with CVD, even though not all individuals respond to antiplatelet therapy in a similar way, being resistant to aspirin. The aim of this study was to determine the prevalence of laboratory defined aspirin resistance in CVD patients worldwide. METHODS: Relevant articles were identified through searching EMBASE, PubMed/ MEDLINE, ISI /Web of Science, Scopus, and the Cochrane Library, from January 2000 to February 2018. The methodological quality of the included studies was critically appraised using the Newcastle-Ottawa scale. The pooled prevalence of laboratory defined aspirin resistance was computed using the Der Simonian-Laird random-effect model. RESULTS: We included 65 studies, with a total of 10,729 patients. The overall prevalence of laboratory defined aspirin resistance in CVD patients was 24.7% ([95%CI 21.4-28.4]. Women were found to be at increased risk of laboratory defined aspirin resistance compared to men, with an odds ratio of 1.16 [95%CI 0.87-1.54]. CONCLUSION: Doctors and healthcare providers should pay special attention to aspirin resistance since lack of awareness could cause problems and increase mortality in these patients, if not properly treated with higher aspirin doses.
No takes yet. Share an insight, caveat, or question.
Ebrahimi et al. (2020) conducted a meta-analysis in Cardiovascular disease (n=10,729). Laboratory defined aspirin resistance was evaluated on Prevalence of laboratory defined aspirin resistance (95% CI 21.4-28.4). The overall prevalence of laboratory defined aspirin resistance in cardiovascular disease patients was 24.7% (95% CI 21.4-28.4).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: